|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
ABSTRACT |
|---|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The vascular endothelium has a central role in the control of microvascular tone, and it has been proposed that vascular endothelial damage occurs in septic shock, producing multiorgan failure. We have developed a method of detecting circulating endothelial cells (EC) that provides direct evidence of EC shedding in human sepsis. Human umbilical vein endothelial cells (HUVEC) were seeded in whole blood and recovered by isopycnic centrifugation to validate the technique. Blood samples were subsequently taken from 11 healthy volunteers, nine ventilated intensive care unit (ICU) control patients without sepsis, eight patients with sepsis but without shock, and 15 patients with septic shock. EC were identified by indirect immunofluorescence, using antibodies to von Willebrand factor (vWf) and the vascular endothelial growth factor receptor KDR. Mean HUVEC recovery was 86% for 20 to 100 seeded cells/ml of blood. vWf-positive EC counts per milliliter were significantly higher (analysis of variance [ANOVA], p < 0.0001) in patients with sepsis (16.1 ± 2.7 [mean ± SEM]) and septic shock (30.1 ± 3.3) than in healthy (1.9 ± 0.5) or ICU controls (2.6 ± 0.6). KDR-positive EC counts per milliliter were also significantly higher (ANOVA, p < 0.0001) in patients with sepsis (4.2 ± 1.1/ml) and septic shock (10.4 ± 1.2/ml) than in healthy (0.7 ± 0.3/ml) or ICU controls (0.5 ± 0.2/ml). Cell counts made with anti-vWf antibody were consistently higher than those made with anti KDR antibody, but correlation between the two counts was high (r2 = 0.93). The number of circulating KDR-positive EC was significantly higher in patients who died of septic shock than in survivors (12.0 ± 1.6/ml versus 7.1 ± 1.2/ml, p = 0.026). An increase in circulating EC can be identified during sepsis and septic shock. This supports the hypothesis that endothelial damage occurs in human sepsis.
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Sepsis occurs in approximately 1% of all hospital inpatients and accounts for between 20% and 30% of intensive care unit (ICU) admissions (1, 2). Despite modern techniques of resuscitation and organ support, septic shock continues to have a mortality rate in the region of 50%. Septic shock develops during an episode of infection and is characterized by the appearance of hypotension that is resistant to volume replacement alone, and by organ hypoperfusion (3).
Microorganisms have a clear initiating role in septic shock syndrome, but the circulatory disturbances that follow are a result of the release of various toxins and inflammatory mediators (1, 4). Some of these substances are direct bacterial products, but many are released by the host in response to infection. They include both pro- and antiinflammatory cytokines, complement components, platelet-activating factor, prostaglandins, and nitric oxide (NO). These inflammatory mediators cause complex alterations in microvascular flow (5). Vascular dilation and constriction, the presence of arteriovenous shunts, and changes in tissue blood flow as a result of vascular occlusion have all been reported in humans and animals during sepsis (6).
In the past decade, a unifying hypothesis has been developed to explain the vascular changes in septic shock (7) on the basis of the effect of inflammatory mediators on the vascular endothelium (4, 8, 9). The endothelium is involved in the control of vascular tone, vascular permeability, and coagulation (10, 11), and a number of changes in it follow exposure of endothelial cells (EC) and isolated blood vessels to relevant proinflammatory mediators (12). It has therefore been proposed that widespread endothelial damage occurs during human sepsis and leads to organ dysfunction and failure. However, there is little direct evidence for endothelial damage or dysfunction in humans during septic shock.
The presence of increased numbers of circulating EC has previously been reported after various forms of severe vascular disturbance, including sickle cell crisis and myocardial infarction (13). We hypothesized that the severe vascular damage associated with septic shock would also result in endothelial shedding. We therefore measured the number of circulating EC in critically ill patients with sepsis and septic shock.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Subjects
Our study had full ethical approval from the Joint Ethics Committee of Newcastle Health Authority and the University of Newcastle-upon-Tyne. Patients meeting the American College of Chest Physicians/Society for Critical Care Medicine criteria for sepsis and septic shock (21) were identified in the ICUs of the Royal Victoria Infirmary and Newcastle General Hospital, Newcastle-upon-Tyne. The criteria for sepsis included the development of two or more of the following conditions during an episode of infection: a temperature of > 38° C or < 36° C; a heart rate of > 90 beats/min; a respiratory rate of > 20 breaths/min or an arterial carbon dioxide tension (PaCO2) < 4.25 kPa; a white blood cell count > 12 × 109/L; or < 4 × 109/L or the presence of more than 10% immature neutrophils (21). The criteria for septic shock was sepsis-induced hypotension (systolic blood pressure < 90 mm Hg or a reduction of systolic blood pressure of 40 mm Hg or more from baseline) despite adequate fluid resuscitation, along with the presence of perfusion abnormalities (21). ICU controls were recruited from among patients who did not meet the sepsis, septic shock, or systemic inflammatory response criteria of our study (21) but who were sufficiently ill as to require mechanical ventilation. Healthy controls were recruited from among staff members of the University of Newcastle-upon-Tyne and Newcastle-upon-Tyne Hospital. Clinical information on each patient was recorded, including diagnosis, the Acute Physiology and Chronic Health Evaluation (APACHE) II data set (22) on ICU admission, and maximum Sepsis-related Organ Failure Assessment (SOFA) score (23). The following groups were recruited: 15 patients with septic shock, eight patients with sepsis, but without septic shock, nine patients without sepsis from ICUs, and 11 healthy volunteers.
Blood Sampling
In pilot studies it was found that the trauma associated with venipuncture increased the yield of EC in a blood sample. Blood samples were therefore taken from freshly placed, flushed venous cannulae. In healthy controls, a venous cannula (18-gauge) was inserted in a hand or arm vein. In all groups the initial 5-ml blood sample drawn was discarded to minimize EC contamination from the puncture wound of the vascular wall. Following this, 18 ml of venous blood was drawn into tubes containing sodium citrate (0.105 M) as anticoagulant. Samples were collected from patients within 24 h of the initial diagnosis of sepsis or septic shock. Blood samples were analyzed without access to clinical information.
EC Isolation by Isopycnic Centrifugation
Isopycnic centrifugation separates cells on the basis of differences in specific gravity. We have previously described our method of isolating EC with this principle (24). A Percoll (Sigma, Ltd., Poole, UK) suspension was prepared as follows: a solution of 1.54 M sodium chloride (NaCl) with 1 M sodium dihydrogen phosphate (NaH2PO4 · H2O) in deionized water was made up and filter-sterilized with 0.22-µm Flowpore. Percoll of specific gravity 1.130 g/ml was used to prepare a Percoll stock suspension by adding 7 ml of theNaCl/NaH2PO4 · H2O solution to 93 ml of sterile Percoll solution. A volume of 100 ml of Percoll suspension of specific gravity 1.060 g/ml was made up by using 46 ml of Percoll stock suspension, 10 ml of 5 mg/ml human albumin fraction V in water (Sigma), 34 ml of Dulbecco's modified phosphate-buffered saline (PBS), and 10 ml of 3.8% (wt/vol, in water) sodium citrate (prepared from Na3C6H5O7 · 2 H2O. Preparation of the Percoll solution was done under aseptic conditions in a Class II cabinet, and all solutions (except Percoll) were filtered through 0.22-µm Flowpore. The specific gravity of the final Percoll suspension was determined with an electronic laboratory weighing scale (Sartorius), with Percoll of specific gravity 1.130 g/ml as a standard for calibration.
Isolation of Circulating EC
Blood was layered onto an equal volume of Percoll suspension (specific gravity = 1.060 g/ml) and centrifuged at 1,000 × g for 10 min at room temperature. The top cell layer was collected and further centrifuged at 400 × g for 10 minutes to pellet the cells. The cells were then pooled into one tube and resuspended in medium at a final volume of 2 ml. Human umbilical vein endothelial cells (HUVEC), mononuclear cells, and platelets were used as controls. HUVEC were isolated from fresh cords by using collagenase, and were grown in culture. Cells were detached at confluence by using trypsin. Mononuclear cells were prepared by layering blood onto Lymphoprep (Cardinal Laboratories), a separation gradient specifically designed for isolation of lymphocytes from blood, and were centrifuged at 400 × g for 25 min. The top cell layer was transferred into fresh tubes and further centrifuged at 400 × g for 8 min to pellet the cells, which were then resuspended in medium. For preparation of platelet-rich suspension, blood was collected into tubes containing sodium citrate as anticoagulant, and was centrifuged at 1,000 × g for 10 min. The platelet-rich plasma was transferred into a fresh tube and further centrifuged at 400 × g for 10 min to pellet the platelets, which were then resuspended in PBS. Cytospin smears were prepared for each of the cell preparations, and were stained with antibodies.
Identification and Quantitation of Circulating EC
Immunocytochemical methods were used to identify circulating EC. Two antibodies with specificity for EC, a polyclonal antihuman von Willebrand factor (vWf) and a monoclonal anti-vascular endothial growth factor receptor (VEGFr) antibody for the KDR receptor (Sigma), were used to identify and count circulating EC. HUVEC were used as positive controls and mononuclear cells were used as negative controls. Optimal antibody dilutions were determined before the clinical studies were done. Cytospin preparations were made from a standard concentration of HUVEC in PBS, and were stained with antibody to determine the sensitivity of cell detection in vitro. Serial dilutions of HUVEC were seeded into a standard volume of whole blood, and the recovery rate was determined after isolation. Final concentrations of 1,000, 500, 100, 75, 50, 30, 20, 15, and 10 EC per milliliter of whole blood were achieved. Five separate series of seeding experiments were performed.
Indirect Immunofluorescence Technique
One hundred microliters of the cell suspension was used to prepare cytospin smears, which were then stained with the antibodies at a dilution of 1:200 and incubated at 37° C for 30 min. After washing with PBS, the slides were further incubated with the secondary antibodies; goat antirabbit and goat antimouse (for the anti-vWf and anti-VEGFr antibodies, respectively) at 37° C for 30 min. Each test was done in duplicate at a minimum. Nonspecific binding was assessed with an isotype control antibody. Final cell counts were adjusted by subtraction of nonspecific binding. The slides were viewed with a Diaphot EPI fluorescence microscope (490-nm excitation, 520-nm emission) (Nikon, Tokyo, Japan). A conservative approach to cell identification was adopted. Only cells with at least a complete rim of immunofluoresecent staining were counted. In addition, stained cells were differentiated from possible clumps of debris or platelets by changing to phase-contrast light microscopy and assessing the size and morphology of the stained cells. Of these stained cells, those that were between 20 µm and 50 µm in diameter and which were nucleated were counted. All positively stained cells on the slide were directly counted, with the result and expressed as the number of circulating EC per milliliter of whole blood. Staining of cells with both antibodies (anti-vWf and anti-VEGFr), with different fluorochromes (TRITC and fluorescein isothiocyanate, respectively), was done on six samples, to assess the proportion of dual-staining cells.
Cell Culture
EC culture was attempted from all samples obtained from patients with septic shock and all healthy volunteers. The cells were resuspended in a complete medium (Medium 199) supplemented with 20% heat-inactivated fetal calf serum, 2 mM/100 ml L-glutamine, 100 IU/ml penicillin G and 100 g/ml streptomycin, and 300 µg/ml EC growth supplement (all from Sigma). The cells were grown in multiwell plates and incubated at 37° C in 5% CO2. Unattached cells were removed after 24 h by washing the flasks twice with warm medium. The adherent cells were then grown in complete EC medium, with changes of medium made every 7 d. The cells were identified as EC by using monoclonal antibodies to EC markers, including vWf, VEGFr, and CD 105 (endoglin).
Statistical Analysis
Results are presented as the mean ± SEM unless otherwise stated. Analysis of variance (ANOVA) with Bonferroni's correction was used when comparing the four clinical groups. Significance was taken as a value of p < 0.05.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Cell Staining and Retrieval
Mononuclear cell suspensions did not stain with either anti-vWf or anti-KDR antibody. Platelet clumps did stain with anti-vWf antibody, but these were easily distinguished from nucleated cells through phase-contrast microscopy. Platelets and platelet clumps did not stain with anti-KDR antibody. Ninety percent of HUVEC suspended in PBS were identified with the anti-vWf antibody. In whole blood, the mean recovery of vWf-positive cells was 86% (range: 73% to 92%) at seeding concentrations of 20 to 1,000 HUVEC per milliliter. At seeding concentrations below 20 cells per milliliter, recovery fell to less than 40%. Seventy-six percent of HUVEC suspended in PBS were identified with the anti-KDR antibody. In whole blood, the mean recovery of KDR-positive cells was 65% (range: 60% to 85%) at seeding concentrations between 20 and 1,000 HUVEC per milliliter of whole blood. Below this level, recovery was 30% or less.
Patient Data
The mean ages of the four study groups were similar (control group: 58 yr; ICU control group: 48 yr; sepsis group: 62 yr; septic shock group: 58 yr). The sex distributions of the groups were: healthy controls: eight males and three females; ICU controls: seven males and two females; sepsis group: five males and three females; and septic shock group: 11 males and four females. The percentage in each group who were current cigarette smokers were: healthy control group, 45%; ICU control group, 71%; sepsis group, 38%; and septic shock group, 47%.
Respiratory, urinary, and postsurgical intraabdominal infections and primary blood-borne sepsis accounted for the majority of cases of sepsis and septic shock in our series (Tables 1 and 2). APACHE II scores were high in the septic shock group, reflecting the severity of illness in this group of patients, and their elevated SOFA scores showed a high incidence of multiorgan failure. Severity of illness and the degree of multiorgan failure were significantly lower in the ICU control group (Table 3). ICU mortality was 67% in the septic shock group and 22% in the ICU control group. Mortality in the group with sepsis was 13%.
|
|
|
Circulating EC Numbers
Very few circulating EC were identified either in healthy controls or ICU controls. The numbers of vWf-positive cells were 1.9 ± 0.5/ml (mean ± SEM) in healthy controls and 2.6 ± 0.6/ml in ICU controls. Mean KDR-positive cells were 0.7 ± 0.3/ml in healthy controls and 0.5 ± 0.2/ml in ICU controls. There was a significant increase in circulating EC (between-group ANOVA: f = 44.7, p < 0.0001) both in patients with sepsis and those with septic shock (Figures 1 and 2). In patients with sepsis, vWf-positive cells were 16.1 ± 2.7/ml and KDR-positive cells were 4.2 ± 1.1/ml. In patients with septic shock, vWf-positive cells were 30.1 ± 3.3/ml (Figure 3) and KDR-positive cells were 10.4 ± 1.2/ml (between-group ANOVA: f = 26.6, p < 0.0001; Figure 4). The differences between the numbers of circulating vWf-positive and KDR-positive cells in patients with sepsis and septic shock were also significant (p < 0.001 for both groups). Absolute cell counts were higher with the anti-vWf antibody than with the anti-KDR antibody. The correlation between the two counts was high (r2 = 0.93; Figure 5), and a series of dual-staining studies showed that 84% of the KDR-positive cells were also vWf-positive. There was no significant correlation between the total circulating mononuclear cell count and the number of vWf-positive or KDR-positive cells detected in patients with septic shock.
|
|
|
|
|
The number of circulating KDR-positive EC was significantly higher in patients who died of septic shock than in survivors (12.0 ± 1.6/ml versus 7.1 ± 1.2/ml, p = 0.026). The difference between numbers of vWf-positive cells in the survivors and nonsurvivors of septic shock was not significant (34.0 ± 4.2/ml, versus 23.4 ± 3.8/ml, p = 0.09).
Cell Culture
EC were successfully cultured from six of the 15 patients with septic shock, but from none of the controls. Successful cultures were obtained from patients with the highest circulating cell counts. The cells attained between 50% and 80% confluence in 4 to 6 wk. The cells were confirmed as endothelial by the appearance of characteristic "cobblestoning" and with fluorescent antibodies to vWF, KDR, and endoglin. From 70 to 90% of cultured cells were positive for these markers.
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
We found an increase in circulating EC in patients with sepsis and septic shock as compared with both healthy volunteers and ICU patients who did not have sepsis. These results can be explained by the hypothesis that the vascular endothelium is the principal target of the inflammatory response in sepsis, and that widespread vascular damage and disruption occur to this endothelium (2, 4, 8). Our findings of an increase in circulating EC in patients with sepsis but without shock suggest that endothelial damage precedes the clinical development of organ failure. We also found that the mean number of circulating KDR-positive EC was significantly higher in patients who died of septic shock. These observations support the view that the magnitude of increase in circulating cell numbers in sepsis is related to the severity of vascular injury.
The endothelium modulates vascular tone, has important interactions with the coagulation system, and plays a major role in the movement of circulating leukocytes into various tissue beds (10, 11, 25). There is considerable indirect evidence for changes in vascular endothelial function in septic shock. A large number of in vitro studies have demonstrated that exposure of EC to lipopolysaccharide and proinflammatory cytokines initiates a series of molecular programs that alter cell function and may lead to cell dysfunction and damage (12). Stimulated EC upregulate surface adhesion molecules, express and release procoagulant factors, and secrete vasoactive compounds that include endothelins, NO, and prostaglandins. All of these substances and molecules have been implicated in the pathogenesis of septic shock (1).
Evidence for involvement of the vascular endothelium in human septic shock is less clear. There are surprisingly few studies of endothelial ultrastructure in human sepsis, but postmortem studies of patients who died of sepsis-related acute respiratory distress syndrome (ARDS) showed patchy EC swelling and injury (26). Skin biopsy specimens from patients with sepsis resulting from peritonitis showed upregulation of intercellular adhesion molecule-1 on vascular EC (27), and adhesion-molecule upregulation has also been reported on cultured pulmonary microvascular cells taken from patients who died of ARDS (28). Widespread endothelial damage has been reported in a number of studies of animals injected with lethal doses of endotoxin. These include endothelial separation from the basement membrane in primates (29) and vascular EC detachment and loss in primates (30), dogs (31), and rats (32).
Circulating EC have previously been detected in humans through immunofluorescence, immunohistochemical, and flow cytometric techniques (14). George and coworkers, using a flow cytometric method, detected a significant number of circulating EC after venous trauma (16). Sbabati and associates, using an immunofluorescence method, reported a rise in circulating EC following cardiac catheterization (19), and Mutin and colleagues reported increased circulating EC during myocardial infarction in humans (13). Solovey and coworkers, using an immunohistochemical method, found raised circulating numbers of EC during sickle cell crisis (20). Increased numbers of circulating EC have also been reported in humans during cytomegalovirus and rickettsial infections (14, 15, 17, 18). In addition, increased numbers of circulating EC have been found during experimental endotoxemia in the dog (31). In all of these studies, few circulating EC were detected in control subjects, and the order of magnitude of increase in cell numbers in patients was similar to that in the current study (10 to 100 cells/ml blood).
The detection of rarely circulating EC requires specific antibodies to EC receptors. We used two different antibodies to EC receptors, and also used morphologic criteria, to identify EC. vWf is synthesized by EC and subsequently released onto the cell surface (33). It is not completely specific for EC, since it is also synthesized by platelets. However, additional size and morphologic criteria were used to identify the EC in our study. Vascular endothelial growth factor (VEGF) is a cytokine with a major role in angiogenesis (34). Vascular EC express two VEGF receptors. VEGF-R1, or flt-1, is also expressed on monocytes, whereas VEGF-R2, or KDR, is expressed only on EC, pancreatic duct cells, and human testicular tissue. The anti-KDR antibody used in our study should be a highly specific marker for circulating EC, since it is absent on other circulating hemopoetic cells.
In the present study, we detected a consistently higher level of EC with the anti-vWf antibody than with antibody to KDR. The majority of KDR-positive cells were also vWF-positive, and the correlation between the numbers of these two kinds of EC, on a subject-by-subject basis, was high (r2 = 0.93). This suggests that the KDR-positive EC were a subset of the vWf-positive cells. The difference in cell numbers detected with the two antibodies probably indicates a difference in antibody-receptor binding or a difference in the number of receptors expressed. We found that in vitro, the sensitivity of the polyclonal anti-vWF antibody was higher than that of the monoclonal anti-KDR antibody, with 90% of HUVEC staining with the anti-vWF antibody as compared with 75% that were stained with the anti-KDR antibody. This is likely to reflect the higher number of epitopes recognized by the polyclonal anti-vWF antibody than by the monoclonal anti-KDR antibody.
In summary, we have shown that patients with sepsis and septic shock have increased numbers of circulating EC. These findings support the hypothesis that widespread endothelial damage occurs in human sepsis.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Dr. S. V. Baudouin, Department of Anaesthesia, Royal Victoria Infirmary, Newcastle-upon-Tyne, NE1 4LP, UK. E-mail: s.v.baudouin{at}ncl.ac.uk
(Received in original form December 8, 1999 and in revised form June 2, 2000).
Acknowledgments:
Supported by the Wellcome Trust.
| |
References |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351: 1501-1505 [Medline].
2.
Parrillo JE.
Pathogenetic mechanisms of septic shock.
N Engl J Med
1993;
328:
1471-1477
3.
Wheeler AP,
Bernard GR.
Treating patients with severe sepsis.
N Engl J
Med
1999;
340:
207-214
4. Curzen NP, Griffiths MJ, Evans TW. Role of the endothelium in modulating the vascular response to sepsis. Clin Sci 1994; 86: 359-374 [Medline].
5. Sair M, Winlove CP, Evans TW. Microcirculation in sepsis: experimental methods and pathophysiological observations. Clin Sci 1996; 90: 173-182 [Medline].
6. Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 1996; 24: 1072-1078 [Medline].
7.
Evans TW,
Smithies M.
ABC of intensive care: organ dysfunction.
BMJ
1999;
318:
1606-1609
8. Maier RV, Bulger EM. Endothelial changes after shock and injury. New Horizons 1996; 4: 211-223 [Medline].
9. Karima R, Matsumoto S, Higashi H, Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999; 5: 123-132 . [Medline]
10.
Cines DB,
Pollak ES,
Buck CA,
Loscalzo J,
Zimmerman GA,
McEver RP,
Pober JS,
Wick TM,
Konkle BA, et al
.
. Endothelial cells in physiology and in the pathophysiology of vascular disorders.
Blood
1998;
91:
3527-3561
11.
Hunt BJ,
Jurd KM.
Endothelial cell activation: a central pathophysiological process.
BMJ
1998;
316:
1328-1329
12. Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997; 18: 231-240 [Medline].
13.
Mutin M,
Canavy I,
Blann A,
Bory M,
Sampol J,
DignatGeorge F.
Direct evidence of endothelial injury in acute myocardial infarction and
unstable angina by demonstration of circulating endothelial cells.
Blood
1999;
93:
2951-2958
14. Drancourt M, George F, Brouqui P, Sampol J, Raoult D. Diagnosis of Mediterranean spotted fever by indirect immunofluorescence of Rickettsia conorii in circulating endothelial cells isolated with monoclonal antibody-coated immunomagnetic beads. J Infect Disease 1992; 166: 660-663 [Medline].
15.
George F,
Brouqui P,
Boffa MC,
Mutin M,
Drancourt M,
Brisson C,
Raoult D,
Sampol J.
Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells,
thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever.
Blood
1993;
82:
2109-2116
16. George F, Poncelet P, Laurent JC, Massot O, Arnoux D, Lequeux N, Ambrosi P, Chicheportiche C, Sampol J. Cytofluorometric detection of human endothelial cells in whole blood using S-Endo 1 monoclonal antibody. J Immunol Methods 1991; 139: 65-75 [Medline].
17. Grefte A, van der Giessen M, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Disease 1993; 167: 270-277 [Medline].
18. Percivalle E, Revello MG, Vago L, Morini F, Gerna G. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J Clin Invest 1993; 92: 663-670 .
19.
Sbarbati R,
de Boer M,
Marzilli M,
Scarlattini M,
Rossi G,
van Mourik JA.
Immunologic detection of endothelial cells in human whole blood.
Blood
1991;
77:
764-769
20.
Solovey A,
Lin Y,
Browne P,
Choong S,
Wayner E,
Hebbel RP.
Circulating activated endothelial cells in sickle cell anemia.
N Engl J Med
1997;
337:
1584-1590
21.
Bone RC,
Balk RA,
Cerra FB,
Dellinger RP,
Fein AM,
Knaus WA,
Schein RM,
Sibbald WJ.
The ACCP/SCCM Consensus Conference
Committee: definitions for sepsis and organ failure and guidelines for
the use of innovative therapies in sepsis. American College of Chest
Physicians/Society of Critical Care Medicine.
Chest
1992;
101:
1644-1655
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829 [Medline].
23. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonc A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-710 [Medline].
24.
Mahdy Z,
Otun HA,
Dunlop W,
Gillespie JI.
The responsiveness of isolated human hand vein EC in normal pregnancy and in pre-eclampsia.
J Physiol
1998;
508:
609-617
25. Newby AC, Henderson AH. Stimulus-secretion coupling in vascular endothelial cells. Ann Rev Physiol 1990; 52: 661-674 [Medline].
26. Meyrick B. Pathology of the adult respiratory distress syndrome. Crit Care Clin 1986; 2: 405-428 [Medline].
27. Engelberts I, van Hoof SC, Samyo SK, van der Buirman WA, Linden CJ. Generalized inflammation during peritonitis evidenced by intracutaneous E-selectin expression. Clin Immunol Immunopathol 1992; 65: 330-334 [Medline].
28. Grau GE, Mili N, Lou JN, Morel DR, Ricou B, Lucas R, Suter PM. Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome. Lab Invest 1996; 74: 761-770 [Medline].
29. Coalson JJ, Hinshaw LB, Guenter CA, Berrell EL, Greenfield LJ. Pathophysiologic responses of the subhuman primate in experimental septic shock. Lab Invest 1975; 32: 561-569 [Medline].
30. Coalson JJ, Benjamin BA, Archer LT, Beller BK, Spaet RH, Hinshaw LB. A pathologic study of Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Surg Gynecol Obstet 1978; 147: 726-736 [Medline].
31. Gerrity RG, Richardson M, Caplan BA, Cade JF, Hirsh J, Schwartz CJ. Endotoxin-induced vascular endothelial injury and repair: II. Facial injury, en face morphology, (3H) thymidine uptake and circulating endothelial cells in the dog. Exp Mol Pathol 1976; 24: 59-69 [Medline].
32. Sutton ET, Zhou Z, Baker CH, Price JM, Chen Y. Differences in arterial and arteriolar endothelial structure during endotoxin shock. Circ Shock 1993; 41: 71-76 [Medline].
33. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424 [Medline].
34. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999; 237: 59-83 [Medline].
This article has been cited by other articles:
 |
|
 |
|
  B. Gyan, B. Q. Goka, G. O. Adjei, J. K. A. Tetteh, K. A. Kusi, A. Aikins, D. Dodoo, M. L. Lesser, C. P. Sison, S. Das, et al. Cerebral Malaria Is Associated with Low Levels of Circulating Endothelial Progenitor Cells in African Children Am J Trop Med Hyg, April 1, 2009; 80(4): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Foster, E. Shantsila, D. Carruthers, G. Y. H. Lip, and A. D. Blann Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction Rheumatology, March 1, 2009; 48(3): 285 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.S. Bartynski Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1043 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Solodushko, J. C. Parker, and B. Fouty Pulmonary Microvascular Endothelial Cells Form a Tighter Monolayer when Grown in Chronic Hypoxia Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 491 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schouten, W. J. Wiersinga, M. Levi, and T. van der Poll Inflammation, endothelium, and coagulation in sepsis J. Leukoc. Biol., March 1, 2008; 83(3): 536 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gupta, G. J. Rhodes, D. T. Berg, B. Gerlitz, B. A. Molitoris, and B. W. Grinnell Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2 Am J Physiol Renal Physiol, July 1, 2007; 293(1): F245 - F254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.S. Bartynski, J.F. Boardman, Z.R. Zeigler, R.K. Shadduck, and J. Lister Posterior Reversible Encephalopathy Syndrome in Infection, Sepsis, and Shock AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2179 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Boos, G. Y.H. Lip, and A. D. Blann Circulating Endothelial Cells in Cardiovascular Disease J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1538 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Suurna, S. L. Ashworth, M. Hosford, R. M. Sandoval, S. E. Wean, B. M. Shah, J. R. Bamburg, and B. A. Molitoris Cofilin mediates ATP depletion-induced endothelial cell actin alterations Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1398 - F1407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Wesche-Soldato, J. L. Lomas-Neira, M. Perl, L. Jones, C.-S. Chung, and A. Ayala The role and regulation of apoptosis in sepsis Innate Immunity, December 1, 2005; 11(6): 375 - 382. [Abstract] [PDF]
|
|
|
|
 |
|
 E. L. Burnham, W. R. Taylor, A. A. Quyyumi, M. Rojas, K. L. Brigham, and M. Moss Increased Circulating Endothelial Progenitor Cells Are Associated with Survival in Acute Lung Injury Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 854 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al. Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies Clin. Cancer Res., September 15, 2005; 11(18): 6615 - 6624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Wesche, J. L. Lomas-Neira, M. Perl, C.-S. Chung, and A. Ayala Leukocyte apoptosis and its significance in sepsis and shock J. Leukoc. Biol., August 1, 2005; 78(2): 325 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity Clin. Cancer Res., May 1, 2005; 11(9): 3514 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Bannerman, K. T. Eiting, R. K. Winn, and J. M. Harlan FLICE-Like Inhibitory Protein (FLIP) Protects Against Apoptosis and Suppresses NF-{kappa}B Activation Induced by Bacterial Lipopolysaccharide Am. J. Pathol., October 1, 2004; 165(4): 1423 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Quilici, N. Banzet, P. Paule, J.-B. Meynard, M. Mutin, J.-L. Bonnet, P. Ambrosi, J. Sampol, and F. Dignat-George Circulating Endothelial Cell Count as a Diagnostic Marker for Non-ST-Elevation Acute Coronary Syndromes Circulation, September 21, 2004; 110(12): 1586 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Galley and N. R. Webster Physiology of the endothelium Br. J. Anaesth., July 1, 2004; 93(1): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Bannerman and S. E. Goldblum Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L899 - L914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Segal, A. Bihorac, and M. Koc Circulating endothelial cells: tea leaves for renal disease Am J Physiol Renal Physiol, July 1, 2002; 283(1): F11 - F19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. TOBIN Critical Care Medicine in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 565 - 583. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |